Recent News

• 07.15.2026 - A PHASE 1/2, RANDOMIZED, OBSERVER-BLINDED STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF COMBINED VACCINE CANDIDATES AGAINST INFLUENZA AND COVID-19 IN HEALTHY INDIVIDUALS
• 06.26.2026 - An Interventional, Open-Label, Randomized, Multicenter, Phase 2 Study of PF-07220060 Plus Letrozole Compared to Letrozole Alone in Postmenopausal Women 18 Years or Older With Hormone Receptor-Positive, HER2-Negative Breast Cancer in The Neoadjuvant Settin
• 06.10.2026 - Final Report: A Phase 3, Randomized, Double- Blinded, Placebo-Controlled Trial to Evaluate the Safety, Tolerability, and Immunogenicity of Respiratory Syncytial Virus (RSV) Prefusion F Subunit Vaccine in Pregnant Participants Living with HIV and Their Inf
• 06.10.2026 - Final Report: A Phase 3, Randomized, Double- Blinded, Placebo-Controlled Trial to Evaluate the Safety, Tolerability, and Immunogenicity of Respiratory Syncytial Virus (RSV) Prefusion F Subunit Vaccine in Pregnant Participants Living with HIV and Their Inf
• 06.10.2026 - A Phase 4, Randomized, Double-Blind Placebo-Controlled, Efficacy and Tolerability Trial of Rimegepant for the Acute Treatment of Migraine in Adults Unsuitable for Triptan Use
• 06.10.2026 - A Phase 4, Randomized, Double-Blind Placebo-Controlled, Efficacy and Tolerability Trial of Rimegepant for the Acute Treatment of Migraine in Adults Unsuitable for Triptan Use
• 06.05.2026 - A Phase 4, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Tolerability of Rimegepant for the Prevention of Migraine in Adults With a History of Inadequate Response to Oral Preventative Medications
• 05.21.2026 - B3461077
• 02.27.2026 - A Multicenter, Randomized, Double-Blind Phase 3 Study of Palbociclib (Oral CDK 4/6 Inhibitor) Plus Letrozole Versus Placebo Plus Letrozole for the Treatment of Previously Untreated Asian Postmenopausal Women With ER (+), HER2 (-) Advanced Breast Cancer
• 02.18.2026 - An Open-label Extension Study to Evaluate the Long-term Safety of Osivelotor Administered to Participants With Sickle Cell Disease Who Have Participated in an Osivelotor Clinical Trial

Recent Filings

• 07.13.2026 - 4 Statement of changes in beneficial ownership of securities
• 07.01.2026 - 4 Statement of changes in beneficial ownership of securities
• 06.30.2026 - 4 Statement of changes in beneficial ownership of securities
• 06.30.2026 - 4 Statement of changes in beneficial ownership of securities
• 06.30.2026 - 4 Statement of changes in beneficial ownership of securities
• 06.30.2026 - 4 Statement of changes in beneficial ownership of securities
• 06.30.2026 - 4 Statement of changes in beneficial ownership of securities
• 06.30.2026 - 4 Statement of changes in beneficial ownership of securities
• 06.18.2026 - 8-K Current report
• 06.18.2026 - 8-K Current report